Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude Negrier

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 7, 2018
Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteinsSandra Le Quellec, Allison Dane, Nathalie Enjolras, et al.
Thrombosis Research|March 22, 2015
Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activityEloïse Perot, Nathalie Enjolras, Sandra Le Quellec, et al.
Pediatric Blood & Cancer|December 8, 2005
Human herpesvirus 6 infection and transient acquired myelodysplasia in childrenSandrine Kagialis-Girard, Brigitte Durand, Valérie Mialou, et al.
British Journal of Haematology|October 31, 2015
Effect of five therapeutic strategies on the coagulation defect induced by the thrombomodulin c.1611C>A mutationYesim Dargaud, Yohann Jourdy, Sandra Le Quellec, et al.
Thrombosis and Haemostasis|December 9, 2020
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 ProphylaxisMaria Elisa Mancuso, Mark T Reding, Claude Negrier, et al.
Patient Preference and Adherence|August 26, 2021
Patients' Perception of the Impact of Innovation on Hemophilia Care Management Organization: A Qualitative Study Protocol (INNOVHEMO Study)Karen Beny, Benjamin du Sartz de Vigneulles, Valerie Chamouard, et al.
Plos One|September 9, 2022
Multiple criteria decision analysis for therapeutic innovations in a hemophilia care center: A pilot study of the organizational impact of innovation in hemophilia care managementKaren Beny, Amélie Dubromel, Benjamin du Sartz de Vigneulles, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 2, 2016
Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)Claude Negrier, Sophie Voisin, Fariba Baghaei, et al.
Haematologica|December 7, 2007
Thrombin-generating capacity in patients with von Willebrand's diseaseLucia Rugeri, Suzette Beguin, Coenraad Hemker, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 5, 2022
Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective single-centre studyStéphanie Désage, Yesim Dargaud, Sandrine Meunier, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 7, 2018
Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteinsSandra Le Quellec, Allison Dane, Nathalie Enjolras, et al.
Thrombosis Research|March 22, 2015
Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activityEloïse Perot, Nathalie Enjolras, Sandra Le Quellec, et al.
Pediatric Blood & Cancer|December 8, 2005
Human herpesvirus 6 infection and transient acquired myelodysplasia in childrenSandrine Kagialis-Girard, Brigitte Durand, Valérie Mialou, et al.
British Journal of Haematology|October 31, 2015
Effect of five therapeutic strategies on the coagulation defect induced by the thrombomodulin c.1611C>A mutationYesim Dargaud, Yohann Jourdy, Sandra Le Quellec, et al.
Thrombosis and Haemostasis|December 9, 2020
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 ProphylaxisMaria Elisa Mancuso, Mark T Reding, Claude Negrier, et al.
Patient Preference and Adherence|August 26, 2021
Patients' Perception of the Impact of Innovation on Hemophilia Care Management Organization: A Qualitative Study Protocol (INNOVHEMO Study)Karen Beny, Benjamin du Sartz de Vigneulles, Valerie Chamouard, et al.
Plos One|September 9, 2022
Multiple criteria decision analysis for therapeutic innovations in a hemophilia care center: A pilot study of the organizational impact of innovation in hemophilia care managementKaren Beny, Amélie Dubromel, Benjamin du Sartz de Vigneulles, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 2, 2016
Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)Claude Negrier, Sophie Voisin, Fariba Baghaei, et al.
Haematologica|December 7, 2007
Thrombin-generating capacity in patients with von Willebrand's diseaseLucia Rugeri, Suzette Beguin, Coenraad Hemker, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 5, 2022
Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective single-centre studyStéphanie Désage, Yesim Dargaud, Sandrine Meunier, et al.
Pageof 7